Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in pancreatic islet cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 6 Parkinson's papers of 159 | 0.74 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 4819
Sealed predictions
- SCG2 in dopamine neurons, braak+0.02 (p 0.964) → +0.49 (p 0.186)receipt 4858
Swarm cases
receipt 4858: SCG2 in dopamine neurons, braak
- power
- full sample +0.23 (p 0.369, n 18), 95% CI -0.27 to +0.63. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.28 (p 0.254, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.30 (p 0.228, n 18). could be the mix.
- skeptic
- leave-one-out range +0.15 to +0.35, sign flips 0; without severely affected donors +0.23 (p 0.369, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SCG2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts